Further changes to Silence chiefs
This article was originally published in Scrip
Executive Summary
Just one day after appointing Thomas Christely CEO (scripintelligence.com, 20 September 2011), Silence Therapeutics, a RNA interference therapeutics company, has appointed Tony Sedgwick chief business officer. Mr Sedgwick will assume responsibility for broadening Silence's partnerships, having most recently served as CEO of Novacta and chairman of Plastid.